Eisai Co., Ltd.(4523) News

Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.

Financial Results for the Six-Month Period Ended September 30,2025 Reference Data

CONSOLIDATED FINANCIAL REPORT [IFRS] for the Six-Month Period Ended September 30, 2025

Eisai, Jul-Sep (2Q) Net Income Decreases by 9%

Revenue of LEQEMBI (Preliminary Basis)

Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.

FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2025

Eisai, Apr-Jun (1Q) Net Income Increases by 37%

FY 2025 (Ending March 31,2026) First Quarter Financial Results Reference Data

Revenue of LEQEMBI (Preliminary Basis)

Eisai Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.　

Notification Regarding Partial Amendment to the Articles of Incorporation

FY 2024 (Ended March 31,2025) Full Year Financial Results Reference Data

CONSOLIDATED FINANCIAL REPORT [IFRS] for Fiscal 2024 (Year Ended March 31, 2025)

Eisai, 11% Decrease in Net Income for The Current Fiscal Year

Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)

REVENUE OF LEQEMBI (PRELIMINARY BASIS)

Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

Notice Concerning Commencement of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)